Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy

Area of Science:

• Nephrology
• Intensive Care Medicine
• Biochemistry

Background:

• Hypophosphatemia affects up to 80% of patients undergoing continuous renal replacement therapy (CRRT).
• Phosphate supplementation during CRRT is labor-intensive and may not prevent critical phosphate level drops.
• This study investigates a novel phosphate-containing dialysis fluid for hypophosphatemia prevention during CRRT.

Purpose of the Study:

• To evaluate the efficacy of a new phosphate-containing dialysis fluid in preventing hypophosphatemia in intensive care unit patients undergoing CRRT.
• To compare the incidence of hypophosphatemia between standard treatment and treatment with the novel phosphate-containing dialysis fluid.

Main Methods:

• A randomized controlled trial involving 42 intensive care unit patients undergoing hemodiafiltration.
• Patients were divided into three groups: standard treatment with IV phosphate, phosphate solution as dialysate/standard replacement, and phosphate solution as both dialysate and replacement.
• Serum phosphate levels and other electrolytes were monitored throughout the treatment period.

Main Results:

• Standard treatment led to hypophosphatemia in 11 of 14 patients.
• Using the phosphate solution as dialysate and standard replacement fluid reduced hypophosphatemia incidence to 5 of 14 patients.
• Patients receiving the phosphate-containing solution for both dialysate and replacement maintained stable serum phosphate levels without hypophosphatemia.

Conclusions:

• The novel phosphate-containing dialysis and replacement solution effectively prevents hypophosphatemia during CRRT.
• This new solution significantly reduces serum phosphate level variability and eliminates the occurrence of hypophosphatemia.
• The phosphate-containing solution demonstrates a safe and effective method for managing phosphate levels in CRRT patients.